NaV1.8-MAGI1 inhibitor

Channavix Therapeutics is developing a first-in-class analgesic program targeting the interaction between the voltage-gated sodium channel NaV1.8 and the scaffolding protein MAGI1 (Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1). The therapeutic candidate, which includes both lipidated peptidomimetic and small molecule approaches, acts as a decoy to disrupt the NaV1.8-MAGI1 binding interface. This disruption prevents the anchoring of NaV1.8 channels at the neuronal cell surface, making them targets for degradation and effectively silencing pain transmission. Designed for local delivery, the program aims to provide multi-week analgesia for acute post-surgical, neuropathic, and chronic pain (such as osteoarthritis) without the risks of addiction or systemic toxicity associated with traditional analgesics.

Other names

NaV1.8-MAGI1 interaction inhibitorNaV-1.8-MAGI1 interaction inhibitorNaV 1.8-MAGI1 interaction inhibitorlipidated NaV1.8 WW binding domain decoy peptidelipidated NaV1.8 peptidomimeticNaV1.8 Inhibition ProgramNaV-1.8 Inhibition ProgramNaV 1.8 Inhibition Program